Preclinical Models for Drug Selection in Myeloproliferative Neoplasms

Characterization of the TGF- 1 signaling abnormalities in the Gata1low mouse model of myelofibrosis

(2013) M. Zingariello et al.   BLOOD

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-  in a murine model of polycythemia vera

(2013) A. Mullally et al.   BLOOD

Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm

(2013) Santiago Barrio et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mutations and prognosis in primary myelofibrosis

(2013) A M Vannucchi et al.   LEUKEMIA

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

(2013) Costanza Bogani et al.   PLoS One

Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model

(2012) L. Kubovcakova et al.   BLOOD

Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients

(2012) Luisa Vicari et al.   BRITISH JOURNAL OF HAEMATOLOGY

Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients

(2012) Ariel Amaru Calzada et al.   EXPERIMENTAL HEMATOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms

(2011) S. Anand et al.   BLOOD

TNF  facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms

(2011) A. G. Fleischman et al.   BLOOD

New mutations and pathogenesis of myeloproliferative neoplasms

(2011) W. Vainchenker et al.   BLOOD

EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L

(2011) G Wernig et al.   LEUKEMIA

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

(2011) Alfonso Quintás-Cardama et al.   NATURE REVIEWS DRUG DISCOVERY

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

(2011) Y Nakaya et al.   Blood Cancer Journal

Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition

(2010) Giovanni Barosi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

(2010) P. Koppikar et al.   BLOOD

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice

(2010) C. Marty et al.   BLOOD

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

(2010) H. Akada et al.   BLOOD

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia

(2010) J. Li et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells

(2010) Ann Mullally et al.   CANCER CELL

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

CXCR4-independent rescue of the myeloproliferative defect of the gata1low myelofibrosis mouse model by Aplidin®

(2010) Maria Verrucci et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

(2010) F. Baffert et al.   MOLECULAR CANCER THERAPEUTICS

From Palliation to Targeted Therapy in Myelofibrosis

(2010) Alessandro M. Vannucchi   NEW ENGLAND JOURNAL OF MEDICINE

Myeloproliferative disorders

(2008) R. L. Levine et al.   BLOOD

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

(2008) S. Xing et al.   BLOOD

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1low mouse model of the disease

(2008) Anna Rita Migliaccio et al.   EXPERIMENTAL HEMATOLOGY

Hypermethylation ofCXCR4Promoter in CD34+Cells from Patients with Primary Myelofibrosis

(2008) Costanza Bogani et al.   STEM CELLS

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

(2007) R. Tiedt et al.   BLOOD